T-SPOT.TB 结核病检测适用人群_欧弗得官网 | 结核感染检测

免疫功能低下人群有哪些?

许多被诊断患有潜在疾病的人并没有意识到他们的免疫功能受到了损害。¹ 那些免疫系统受到损害的人面临更高感染结核的风险，以及由潜伏性结核病(结核潜伏感染)变为活动性肺结核的风险。疾病预防和控制中心(CDC)公布了以下名单，这些人一旦感染结核分枝杆菌(MTB)，就有较高风险患活动性结核病:^2,3

0

糖尿病患者

34,200,000 糖尿病患者⁴

0

克罗恩病或其他炎症性肠病患者

3,000,000 克罗恩病或其他炎症性肠病患者⁵

0

类风湿性关节炎患者

1,500,000 患有类风湿性关节炎的人⁶

0

艾滋病感染者

1,100,000艾滋病感染者⁷

0

患有慢性肾病的人

37,000,000 患有慢性肾病的人⁸

正在接受免疫抑制治疗的人
最近感染结核的人(在过去2年内)
有未经治疗或未得到充分治疗的活动性结核病病史的人
患有白血病、淋巴瘤或头、颈或肺癌的人
做过胃切除术或空肠搭桥术的人
体重低于理想体重90%的人
吸烟或滥用药物或酒精的人
活动性结核病发病率较高地区的居民

为什么免疫功能低下的人处于危险之中？

免疫系统受损的人面临的风险增加有很多原因。包括:

从结核潜伏感染发展为活动性结核病的风险可能比健康人群高得多⁹
结核病感染会增加基础或共患疾病病情的进展，如HIV¹⁰
药物相互作用和累积毒性会使结核病的管理变得复杂¹¹
T细胞数量减少或功能降低使得针对结核分枝杆菌感染的免疫反应检测难以进行¹²

immunocompromised — 来听听妮可在被诊断为活动性肺结核后面临的挑战

T-SPOT.TB检测不受患者免疫功能的限制或影响，可用于免疫功能低下个体的检测^13,14

T-SPOT.TB检测设计的可靠性，包括清洗和标准化每个患者标本中的细胞数量，即使在有挑战性的患者人群中也获得了临床数据的支持。因此，T-SPOT.TB检测专有的细胞计数技术可使临床医生放心地筛选和检测结核病。¹³

患者群体的多样性对T-SPOT.TB检测结果的准确性没有影响，该产品同样适用于免疫功能低下的人群。

了解更多关于
T-SPOT.TB 检测

联系我们

References

参考资料

Helwick C. Immunosuppression Surprisingly Prevalent in American Adults. Medscape. https://www.medscape.com/viewarticle/871290. Published November 2, 2016. Accessed January 9, 2020.
TB Risk Factors. Centers for Disease Control and Prevention. https://www.cdc.gov/tb/topic/basics/risk.htm. Published March 18, 2016. Accessed January 8, 2020.
CDC – TB 101 – Groups at High Risk for Developing TB Disease – Web Courses – TB. Centers for Disease Control and Prevention. https://www.cdc.gov/tb/webcourses/tb101/page121.html. Accessed January 9, 2020.
National Diabetes Statistics Report. Centers for Disease Control and Prevention. https://www.cdc.gov/diabetes/data/statistics/statistics-report.html Accessed March 11, 2020.
Inflammatory Bowel Disease Data and Statistics. Centers for Disease Control and Prevention. https://www.cdc.gov/ibd/data-statistics.htm Accessed March 11, 2020.
Rheumatoid Arthritis. Yale Medicine. https://www.yalemedicine.org/conditions/rheumatoid-arthritis/ Accessed March 11, 2020.
U.S. Statistics. HIV.gov. https://www.hiv.gov/hiv-basics/overview/data-and-trends/statistics Accessed March 11, 2020.
Kidney Disease: The Basics. National Kidney Foundation. https://www.kidney.org/news/newsroom/factsheets/KidneyDiseaseBasics Accessed March 11, 2020.
Tuberculosis (TB). Centers for Disease Control and Prevention. https://www.cdc.gov/tb/default.htm. Published December 31, 2018. Accessed January 9, 2020.
Recommendations. Guidelines on the Management of Latent Tuberculosis Infection. http://www.ncbi.nlm.nih.gov/books/NBK293812/ Published January 1, 1970. Accessed January 9, 2020.
Global tuberculosis report 2019. World Health Organization. http://www.who.int/tb/publications/global_report/en/ Published January 7, 2020. Accessed January 9, 2020.
Lai CC, Tan CK,et al. Diagnostic performance of whole-blood interferon-γ assay and enzyme-linked immunospot assay for active tuberculosis. J Microbiol Immunol Infect. 2011 Oct;44(5):406-7. doi: 10.1016/j.jmii.2011.07.002. Epub 2011 Sep 8.
Oxford Immunotec. T-SPOT.TB Package Insert PI-TB-US-0001 V7. Abingdon, UK. February 2019.
Qiagen. QuantiFERON-TB Gold Plus (QFT-Plus) ELISA Package Insert. 1095849 Rev. 06. November 2019.

QFT is a registered trademark of The Qiagen Group.